Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacqueline Cloos

Showing results (131-140 of 172) with videos related to

Pageof 18
Sort By:
Ebiomedicine|December 25, 2018
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesotheliomaRocco Sciarrillo, Anna Wojtuszkiewicz, Btissame El Hassouni, et al.
Blood|June 5, 2010
High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemiaHendrik J M de Jonge, Peter J M Valk, Nic J G M Veeger, et al.
Experimental Hematology & Oncology|January 12, 2013
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitorsSue Ellen Verbrugge, Marjon Al, Yehuda G Assaraf, et al.
Journal of Visualized Experiments : Jove|March 20, 2018
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid LeukemiaJacqueline Cloos, Jeffrey R Harris, Jeroen J W M Janssen, et al.
American Journal of Hematology|March 19, 2026
Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive ChemotherapyLukas H Haaksma, Tom Reuvekamp, Kasper J Croese, et al.
Cancer Cell|September 14, 2010
In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastomaShahryar E Mir, Philip C De Witt Hamer, Przemek M Krawczyk, et al.
Blood|November 4, 2010
High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)Jenny E Kuipers, Eva A Coenen, Brian V Balgobind, et al.
Journal of the National Cancer Institute|May 28, 2010
Effect of noncompetitive proteasome inhibition on bortezomib resistanceXiaoming Li, Tabitha E Wood, Remco Sprangers, et al.
Pediatric Blood & Cancer|September 17, 2021
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 StudyKim Klein, H Berna Beverloo, Martin Zimmermann, et al.
Annals of Hematology|October 4, 2024
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcomeGerwin Huls, Dana A Chitu, Lidwine Tick, et al.
Pageof 18

Showing results (131-140 of 172) with videos related to

Sort By:
Pageof 18
Ebiomedicine|December 25, 2018
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesotheliomaRocco Sciarrillo, Anna Wojtuszkiewicz, Btissame El Hassouni, et al.
Blood|June 5, 2010
High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemiaHendrik J M de Jonge, Peter J M Valk, Nic J G M Veeger, et al.
Experimental Hematology & Oncology|January 12, 2013
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitorsSue Ellen Verbrugge, Marjon Al, Yehuda G Assaraf, et al.
Journal of Visualized Experiments : Jove|March 20, 2018
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid LeukemiaJacqueline Cloos, Jeffrey R Harris, Jeroen J W M Janssen, et al.
American Journal of Hematology|March 19, 2026
Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive ChemotherapyLukas H Haaksma, Tom Reuvekamp, Kasper J Croese, et al.
Cancer Cell|September 14, 2010
In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastomaShahryar E Mir, Philip C De Witt Hamer, Przemek M Krawczyk, et al.
Blood|November 4, 2010
High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)Jenny E Kuipers, Eva A Coenen, Brian V Balgobind, et al.
Journal of the National Cancer Institute|May 28, 2010
Effect of noncompetitive proteasome inhibition on bortezomib resistanceXiaoming Li, Tabitha E Wood, Remco Sprangers, et al.
Pediatric Blood & Cancer|September 17, 2021
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 StudyKim Klein, H Berna Beverloo, Martin Zimmermann, et al.
Annals of Hematology|October 4, 2024
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcomeGerwin Huls, Dana A Chitu, Lidwine Tick, et al.
Pageof 18